BNCT for primary synovial sarcoma
BNCT for primary synovial sarcoma
复制标题
DOI：
10.1016/j.apradiso.2020.109407
复制
发表时间：
2021-03-01
影响因子：
1.6
通讯作者：
Hirose, Takanori
中科院分区：
文献类型：
--
作者：
Fujimoto, Takuya;Suzuki, Minoru;Hirose, Takanori
滑膜肉瘤是一种罕见的肿瘤，需要新的治疗方法。一名46岁女性，左大腿原发性单相滑膜肉瘤累及坐骨神经，因担心患肢可能出现功能障碍而拒绝手术，接受了两个疗程的硼中子俘获治疗（BNCT）。肿瘤缩小后被完全切除，且无后续复发。患者现在能够独立行走，未观察到局部复发，这表明BNCT作为滑膜肉瘤的辅助治疗具有适用性。需要进一步研究分析并积累更多经验，以确认BNCT对滑膜肉瘤应用的实际疗效影响。
Synovial sarcoma is a rare tumor requiring new treatment methods. A 46-year-old woman with primary monophasic synovial sarcoma in the left thigh involving the sciatic nerve, declining surgery because of potential dysfunction of the affected limbs, received two courses of BNCT. The tumor thus reduced was completely resected with no subsequent recurrence. The patient is now able to walk unassisted, and no local recurrence has been observed, demonstrating the applicability of BNCT as adjuvant therapy for synovial sarcoma. Further study and analysis with more experience accumulation are needed to confirm the real impact of BNCT efficacy for its application to synovial sarcoma.